In patients with systemic vasculitis like ANCA-associated vasculitis (AAV), glucocorticoid use and respiratory disease are linked with severe COVID-19 outcomes, a recent study reports. “Together with reports of other cohorts exposed to immunosuppressant medication, these data could inform future public health guidance for individuals with autoimmune disease,” the researchers wrote. The study, “Risk factors for severe outcomes in patients with systemic vasculitis & COVID‐19: a bi‐national registry‐based cohort study,” was published in the journal Arthritis…

You must be logged in to read/download the full post.